Relay (RLAY) Chief Corporate Development Officer Peter Rahmer Sells Shares

What Happened

Peter Rahmer, Relay Therapeutics' Chief Corporate Development Officer, sold 4,508 shares in an open-market transaction on August 26, 2026. The weighted average sale price was $20.03 per share, for total proceeds of approximately $90,295. This was a sale (routine disposition) rather than a purchase.

Key Details

• Transaction date: August 26, 2026 (reported on Form 4 filed August 28, 2026). The filing appears to be timely (filed within two business days of the trade).
• Transaction type/code: Sale (S) — open market or private sale.
• Shares sold: 4,508; weighted average price: $20.03; total value: ~$90,295.
• Price range/multiple trades: Executed in multiple trades at prices from $20.00 to $20.11 (weighted average reported). The filer offers to provide per-trade breakdown on request to the SEC or issuer.
• Plan disclosure: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted October 31, 2025.
• Holdings after transaction: Not specified in the provided filing excerpt. Footnote indicates holdings include 6,102 shares underlying restricted stock units.

Context

Sales under 10b5-1 plans are prearranged and typically indicate scheduled disposals rather than real‑time trading based on nonpublic information. This filing is informational; it does not, by itself, indicate the insider’s view on the company’s outlook. If you want the per-trade price breakdown or the reporter’s post-transaction holdings, those details can be requested from the SEC staff or the issuer as noted in the footnote.